Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008

200720062004

Jul 17, 2017

Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Samuel H. Israel as vice president, chief legal officer and general counsel. "I am very pleased to welcome Sam to the Lannett...

More
Jul 14, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Cyproheptadine...

More
Jun 26, 2017
--New Dosage Strengths of 5 mg/325 mg, 7.5 mg/325 mg and 10 mg/325 mg Represent Lion's Share of the Market and Complement Previously Approved Dosage Strengths--

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Hydrocodone...

More
Jun 22, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Hydrocodone...

More
Jun 20, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that Patrick G. LePore has been appointed to the company's Board of Directors, effective July 1, 2017. The addition of LePore will increase the...

More
Jun 19, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Niacin...

More
Jun 16, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Amantadine...

More
May 26, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that its chief executive officer, Arthur Bedrosian, received a top rating in a report by Owler, the world's largest community-based business...

More
May 16, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Levocetirizine...

More
May 9, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that the company voluntarily paid down the remaining principal balance of $25 million against its existing revolving credit facility. "Since...

More
 

print email rss
Lannett Investor Relations
Lannett Company Products